Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Envafolimab |
Trade Name | |
Synonyms | KN035 |
Drug Descriptions |
Envafolimab (KN035) is a nanobody that targets PD-L1 (CD274) and prevents interaction with PD-1 (PDCD1), potentially resulting in decreased tumor growth (PMID: 28280600). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | 2102192-68-5 |
NCIT ID | C129714 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Doxorubicin + Envafolimab + YH001 | Doxorubicin Envafolimab YH001 | 0 | 1 |
Envafolimab | Envafolimab | 0 | 2 |
Envafolimab + Fluorouracil + Leucovorin + Oxaliplatin | Envafolimab Fluorouracil Leucovorin Oxaliplatin | 0 | 0 |
Envafolimab + Ipilimumab | Envafolimab Ipilimumab | 0 | 1 |
Envafolimab + YH001 | Envafolimab YH001 | 0 | 1 |